Novavax (NVAX) Preferred Stock Liabilities (2020)
Novavax (NVAX) posted quarterly Preferred Stock Liabilities of $199.8 million for Q3 2020, little changed quarter-over-quarter from $199.8 million in Q2 2020.
Novavax (NVAX) Preferred Stock Liabilities (2020) Analysis & Trends
Novavax's Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $199.8 million for Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 199.82 Mn |
| Jun 30, 2020 | 199.82 Mn |